Ultragenyx Pharmaceutical reported $0 in Loan Capital for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Loan Capital Change
Alnylam Pharmaceuticals ALNY:US USD 1.02B 967K
Aptinyx Inc APTX:US USD 24.71M 211K
Biomarin Pharmaceutical BMRN:US USD 1.08B 1.17M
Esperion Therapeutics ESPR:US USD 259.9M 412K
Insmed INSM:US USD 1.15B 347.41M
Karyopharm Therapeutics KPTI:US USD 302.82M 69K
Kyowa Hakko Kirin 4151:JP JPY 17.55B 1.8B
Moderna Inc MRNA:US USD 912M 10M
Ptc Therapeutics PTCT:US USD 1.28B 294.53M
Puma Biotechnology PBYI:US USD 98.31M 313K
Regeneron Pharmaceuticals REGN:US USD 2.7B 300K
Sarepta Therapeutics SRPT:US USD 1.54B 1.52M
Vertex Pharmaceuticals VRTX:US USD 471.6M 29.3M